A Phase 2 interventional study of activated recombinant human factor VII in Acquired Bleeding Disorder and Cirrhosis, sponsored by Novo Nordisk A/S. Completed at 44 sites in 12 countries. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2017-01-13.
Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 172 studies in Fibrosis with a site in France — 34 open to participants now, 39 under way, 4 of them phase 3. Fibrosis · France.
Among the 172 studies in Fibrosis with a site in France, this one is the 38th largest by enrollment of the 117 interventional ones that give a count, is one of 4 that started in 2004, is one of 24 in phase 2, and was the 4th registered.
1,271 studies on the registry are indexed under Fibrosis; 277 are open to participants now.
Browse Fibrosis studies →34 of the 172 studies in Fibrosis with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Hospices Civils de Lyon · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–70
Centre Hospitalier Universitaire Dijon · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Besancon · Sites in France
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 196 Fibrosis studies recruiting now, 111 (57%) set no upper age limit and 53 (27%) stop at 75 or younger; 15 take children under 18; 19 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
172 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 27 · Phase 3 31 · Phase 4 4
First in 1994; this study’s year is marked. 4 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 265 is above the median of 63 across 841 interventional studies indexed under Fibrosis.
Median enrollment 135 across the 117 interventional studies, 200 across the 54 observational. Of the 114 that completed or were terminated, 27 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 172 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Novo Nordisk A/S has 2 studies filed under Fibrosis — fewer than ten, so there is no comparison to draw.
9 of the studies in Fibrosis with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05874492Association Francaise pour la Recherche ThermaleEvaluation of the Medical Benefit of Spa Therapy on Fibrosis After Radiotherapy for Breast Cancer or UADT (Upper Aerodigestive Tract) Cancer | 2026-12 |
| NCT06599892Hospices Civils de LyonCF Organization of Care in the Era of Highly Effective Modulator. | 2026-12-31 |
| NCT06327308Centre Hospitalier Universitaire de BesanconEvaluation of Cirrhotic Cardiomyopathy by Cardiac MRI in Patients Waiting for Liver Transplant. | 2027-03-11 |
| NCT06687265Assistance Publique - Hôpitaux de ParisEffects of Metformin on Hepatic Venous Pressure Gradient in Patients With Cirrhosis and Portal Hypertension | 2027-03-30 |
| NCT06755632Assistance Publique - Hôpitaux de ParisScreening of Patients With Hepatic Fibrosis or Cirrhosis B and C | 2027-06-19 |
Add all 9 to your calendar (.ics) → With an account.
Among the 172 studies in Fibrosis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Asia and Europe. The trial is planned to investigate the effectiveness and safety of NovoSeven® in patients with advanced cirrhosis and active variceal bleeding.
Inclusion Criteria:
Treatment failure
Time frame: Within 5 days after first trial product administration
Mortality
Rebleeding
Control of acute bleeding
The record gives a start of Apr 2004, a primary completion of Aug 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Recombinant FVIIa